Trial Profile
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 29 May 2023 Planned End Date changed from 30 Sep 2024 to 1 Dec 2024.
- 29 May 2023 Planned primary completion date changed from 31 Mar 2024 to 1 Jun 2024.
- 29 May 2023 Status changed from recruiting to active, no longer recruiting.